TinyGemsBreaks Archive - Page 6 of 130

FridayJun 27, 2025 10:20 am

TinyGemsBreaks – Calidi Biotherapeutics Inc. (NYSE American: CLDI) Highlights 2025 Pipeline Progress and Strategic Focus in Shareholder Letter

Calidi Biotherapeutics (NYSE American: CLDI), a clinical-stage biotech company developing systemic oncolytic targeted immunotherapies, released a shareholder letter from CEO Eric Poma, PhD, outlining a transformative year for the company. Since Poma’s appointment in April 2025 and the addition of Dr. Guy Travis Clifton as Chief Medical Officer, Calidi has streamlined operations and advanced its RedTail platform—a systemically delivered virotherapy designed to target metastatic cancers and deliver genetic payloads. Preclinical data presented at AACR and ASCO showcased RedTail’s tumor selectivity and immune modulation potential, driving partnership discussions and IND-enabling studies for lead candidate CLD-401, with a filing expected by end…

TuesdayJun 24, 2025 3:28 pm

TinyGemsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Highlights GBM Treatment Insights in KOL Segment Featuring Dr. Erin Dunbar

CNS Pharmaceuticals (NASDAQ: CNSP) announced the release of a Virtual Investor KOL Connect segment featuring Dr. Erin Dunbar, Director of Neuro-Oncology at Piedmont Atlanta Hospital and founding physician of its Brain Tumor Center. Dr. Dunbar discussed the patient journey and current treatment options for Glioblastoma Multiforme (GBM), highlighting CNS’s lead product candidate, TPI 287, and its therapeutic potential for GBM and future metastatic tumor indications. To view the full press release, visit https://ibn.fm/f2RrI About CNS Pharmaceuticals Inc. CNS Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of…

TuesdayJun 24, 2025 2:46 pm

TinyGemsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Reports Positive Preclinical Results for INM-901 in Alzheimer’s Neuroinflammation Model

InMed Pharmaceuticals (NASDAQ: INM), a pharmaceutical company developing small molecule drug candidates for diseases with high unmet medical needs, announced new preclinical data showing that INM-901 significantly reduces inflammation in ex vivo models of neuroinflammation. The compound demonstrated a dose-dependent and statistically significant reduction in pro-inflammatory cytokines IL-6, IL-1β, IL-2, KC/Gro, and inflammasome marker NLRP3—key factors in Alzheimer’s disease progression. Notably, the effects were independent of amyloid beta or tau pathology, highlighting INM-901’s broader potential in treating neurodegenerative diseases. The orally administered compound also targets CB1/CB2 receptors and PPARs and has shown improvements in cognition and behavior in long-term animal…

MondayJun 23, 2025 11:40 am

TinyGemsBreaks – Vision Marine Technologies Inc. (NASDAQ: VMAR) Acquires Nautical Ventures to Launch First Integrated Electric Boat Dealership in North America

Vision Marine Technologies (NASDAQ: VMAR), a leader in high-voltage electric marine propulsion, has acquired Nautical Ventures Group, a top U.S. boat dealership and 2024 Boating Industry “Dealer of the Year.” The move establishes North America’s first combined electric boat propulsion and dealership platform, pairing Vision Marine’s E-Motion(TM) powertrain with Nautical Ventures’ extensive retail network, inventory, and service capabilities. With nine Florida locations and a portfolio that includes brands like Axopar, Yamaha, and Beneteau, Nautical Ventures provides Vision Marine direct access to one of the world’s most active boating markets. The acquisition adds direct-to-consumer capabilities, expanded revenue streams, and positions the…

WednesdayJun 18, 2025 2:40 pm

TinyGemsBreaks – D-Wave Quantum Inc. (NYSE: QBTS) Signs MOU to Advance Quantum Computing in South Korea

D-Wave Quantum Inc. (NYSE: QBTS) (“D-Wave”), a leader in quantum computing systems, software, and services, announced that it has signed a memorandum of understanding (MOU) with Yonsei University and Incheon Metropolitan City aimed at accelerating quantum computing adoption in South Korea. Supporting the region’s ambition to become a global quantum technology hub, the MOU outlines plans to work together on research, talent development, and use case exploration across biotechnology, materials science and other sectors. The MOU also facilitates the organizations’ collaborative efforts towards the acquisition of a D-Wave Advantage2™ quantum system at the Yonsei University International Campus in Songdo, Yeonsu-gu, Incheon.…

WednesdayJun 18, 2025 2:23 pm

TinyGemsBreaks – Authentic Holdings (OTC: AHRO) Subsidiary Maybacks Global Launches Hit Broadcast of Ring of Combat via Swerve TV

Authentic Holdings (OTC: AHRO) announced a major licensing agreement between its subsidiary Maybacks Global Entertainment, LLC and Swerve TV, marked by a successful debut broadcast of "Ring of Combat" from the Tropicana in Atlantic City on June 13. The event exceeded expectations, drawing substantial viewership and social media traction across Swerve TV's extensive platform, which reaches 80% of U.S. and Canadian households and over 5 million combat sports fans. The collaboration showcased the legacy of "Ring of Combat," a promotion known for launching 165 fighters into the UFC, including champions like Matt Serra and Merab Dvalishvili. The broadcast success has…

FridayJun 13, 2025 3:40 pm

TinyGemsBreaks – SolarBank Corp.’s (NASDAQ: SUUN) (Cboe CA: SUNN) (FSE: GY2) Forest Hill Rd Project Adds to Growing Development Pipeline

Disseminated on behalf of SolarBank Corporation SolarBank (NASDAQ: SUUN) (Cboe CA: SUNN) (FSE: GY2) was featured in a recent article that discussed its momentum with the development of its Forest Hill Rd solar project in upstate New York. “The 4.584 megawatt DC installation will operate as a community solar facility, contributing renewable energy to the local grid and offering cost savings to approximately 540 homes,” reads the article. “The project adds to SolarBank’s growing development pipeline, which now exceeds one gigawatt and already includes several solar projects in upstate New York. It also represents continued expansion in the U.S. market at…

TuesdayJun 10, 2025 1:06 pm

TinyGemsBreaks – Calidi Biotherapeutics Inc. (NYSE American: CLDI) Taps Biotech Veteran to Lead Next Phase of Growth

Calidi Biotherapeutics (NYSE American: CLDI) recently announced the appointment of Eric Poma, PhD, as its new chief executive officer and member of the board of directors. The company was featured in an article that reads, “As Calidi Biotherapeutics continues to pioneer targeted antitumor virotherapies, the appointment of Dr. Poma as CEO represents a strategic move to harness experienced leadership for the company’s next phase of growth. His extensive background in oncology, successful track record in fundraising and strategic partnerships, and comprehensive understanding of the biotech landscape position him to effectively steer Calidi’s innovative therapies through clinical development and toward commercialization.” To…

TuesdayJun 10, 2025 9:10 am

TinyGemsBreaks – Mullen Automotive Inc. (NASDAQ: MULN) Transfers Indiana Facility to Settle Legal Dispute with GEM

Mullen Automotive (NASDAQ: MULN) has finalized a settlement with GEM Yield Bahamas Limited and GEM Global Yield LLC SCS, resolving all outstanding legal disputes. As part of the agreement, Mullen has transferred full ownership of its Mishawaka, Ind. manufacturing facility to GEM, satisfying a prior federal court judgment. The move ends all related litigation and allows Mullen to refocus on its operational goals. To view the full press release, visit https://ibn.fm/LrzjD About Mullen Automotive Inc. Mullen Automotive is a Southern California-based automotive company building the next generation of commercial electric vehicles (“EVs”) with two United States-based vehicle plants located in…

ThursdayJun 05, 2025 1:39 pm

TinyGemsBreaks – Calidi Biotherapeutics Inc. (NYSE American: CLDI) Unveils Promising Data on CLD-401 at ASCO 2025

Calidi Biotherapeutics (NYSE American: CLDI) is a clinical-stage biotechnology company pioneering the development of systemic oncolytic targeted immunotherapies with the ability to deliver genetic payloads. The company unveiled promising new data on its lead RedTail platform candidate, CLD-401, at the American Society of Clinical Oncology (“ASCO”) Annual Meeting. The announcement reads, “Calidi has previously demonstrated its pioneering efforts in developing an enveloped form of its proprietary oncolytic virus that is significantly more resistant to immune clearance than non-enveloped forms, allowing for systemic delivery and efficacy in syngeneic tumor-bearing pre-clinical models. Calidi has further advanced this technology with CLD-401, its first…

Spotlighting undiscovered companies with enormous upside potential.

Contact us: (512) 354-7000

TinyGemsBreaks